[go: up one dir, main page]

PE20090805A1 - COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL - Google Patents

COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL

Info

Publication number
PE20090805A1
PE20090805A1 PE2008000621A PE2008000621A PE20090805A1 PE 20090805 A1 PE20090805 A1 PE 20090805A1 PE 2008000621 A PE2008000621 A PE 2008000621A PE 2008000621 A PE2008000621 A PE 2008000621A PE 20090805 A1 PE20090805 A1 PE 20090805A1
Authority
PE
Peru
Prior art keywords
combination
drospirenone
estradiol
oral contraceptive
contraceptive
Prior art date
Application number
PE2008000621A
Other languages
English (en)
Inventor
Vladimir Hanes
Hartmut Blode
Rolf Schurmann
Bernd Dusterberg
Joachim Marr
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39745001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090805(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20090805A1 publication Critical patent/PE20090805A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE ENTRE 2,0 MG Y 3,0 MG DE DROSPIRENONA Y ENTRE 1,0 MG Y 2,0 MG DE 17BETA-ESTRADIOL, DONDE ADEMAS DEL ESTROGENO Y LA DROSPIRENONA DICHA COMBINACION TAMBIEN PUEDE CONTENER TETRAHIDROFOLATO Y METAFOLINA. DICHA COMBINACION ES UTIL EN LA CONTRACEPCION ORAL FEMENINA
PE2008000621A 2007-04-05 2008-04-07 COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL PE20090805A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91032607P 2007-04-05 2007-04-05
US3528508P 2008-03-10 2008-03-10
US4049408P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
PE20090805A1 true PE20090805A1 (es) 2009-07-25

Family

ID=39745001

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000621A PE20090805A1 (es) 2007-04-05 2008-04-07 COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL

Country Status (15)

Country Link
US (1) US20090023693A1 (es)
EP (1) EP2150257A2 (es)
JP (1) JP2010523512A (es)
CN (1) CN101674837A (es)
AR (1) AR065971A1 (es)
AU (1) AU2008235006A1 (es)
BR (1) BRPI0810049A2 (es)
CA (1) CA2683093A1 (es)
CL (1) CL2008000999A1 (es)
IL (1) IL201302A0 (es)
MX (1) MX2009010763A (es)
PE (1) PE20090805A1 (es)
TW (1) TW200904452A (es)
UY (1) UY31010A1 (es)
WO (1) WO2008122439A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DK2419108T3 (en) 2009-04-14 2016-12-05 Hra Pharma Lab A method for on-demand control of conception,
JP5852639B2 (ja) * 2010-04-15 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ｈｒｔのための低用量固体経口投与形態
CN102985070A (zh) * 2010-04-15 2013-03-20 拜耳知识产权有限责任公司 用于hrt的极低剂量的固体口服剂型
CA2989975C (en) * 2015-06-23 2021-10-12 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101019361B1 (ko) * 1999-08-31 2011-03-07 바이엘 쉐링 파마 악티엔게젤샤프트 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
AR065971A1 (es) 2009-07-15
BRPI0810049A2 (pt) 2015-05-05
UY31010A1 (es) 2008-11-28
IL201302A0 (en) 2010-05-31
CN101674837A (zh) 2010-03-17
US20090023693A1 (en) 2009-01-22
CL2008000999A1 (es) 2008-10-10
MX2009010763A (es) 2009-10-28
TW200904452A (en) 2009-02-01
JP2010523512A (ja) 2010-07-15
CA2683093A1 (en) 2008-10-16
WO2008122439A3 (en) 2009-07-23
EP2150257A2 (en) 2010-02-10
WO2008122439A2 (en) 2008-10-16
AU2008235006A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
AU2010308458A8 (en) Orally transformable tablets
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
MX2010004353A (es) Combinación anticonceptiva oral entiemética.
NI201000183A (es) Regímenes de dosificación de antiprogestina.
GT200800038A (es) Metodo para prevenir la contracepción hormonal contra demanda
GT200900090A (es) Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina
CR11493A (es) Sistema de administracion vaginal
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
PE20140925A1 (es) Composicion farmaceutica que comprende un precursor de esteroides sexuales
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CR9531A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
PE20070208A1 (es) Anticoncepcion oral con trimegestona
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
SV2017005602A (es) Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
CL2015001368A1 (es) Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta".
CR11211A (es) Estratienos 8-beta-sustituidos como estrogenos de accion selectiva
UA108865C2 (uk) Парентеральна фармацевтична композиція у вигляді суспензії уповільненого вивільнення, у низькій та наднизькій дозованій формі, у гормональній терапії при клімактеричному синдромі
PE20080541A1 (es) Forma farmacologica peroral para la anticoncepcion
CL2012003685A1 (es) Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo.

Legal Events

Date Code Title Description
FC Refusal